Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment of various pulmonary diseases, including autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, which has completed the Phase 1 clinical trials for the treatment of patients with narcolepsy; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata. The company is also developing CTP-692, a selective deuterium-modified analog of the endogenous amino acid, D-serine, which is in preclinical studies for use in the treatment of patients with schizophrenia. It has strategic collaborations with Celgene Pharmaceuticals, Inc.; Celgene International Sarl; Celgene Corporation; Avanir Pharmaceuticals, Inc.; and Jazz Pharmaceuticals, Inc. The company was founded in 2006 and is headquartered in Lexington, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CNCE
CUSIPN/A
Phone781-860-0045
Debt
Debt-to-Equity RatioN/A
Current Ratio33.40
Quick Ratio33.40
Price-To-Earnings
Trailing P/E Ratio4.75
Forward P/E Ratio-8.76
P/E GrowthN/A
Sales & Book Value
Annual Sales$143.89 million
Price / Sales3.15
Cash Flow$4.1836 per share
Price / Cash4.63
Book Value$8.63 per share
Price / Book2.24
Profitability
EPS (Most Recent Fiscal Year)$4.08
Net Income$95.63 million
Net Margins67.71%
Return on Equity-23.57%
Return on Assets-20.68%
Miscellaneous
Employees64
Outstanding Shares23,400,000
Concert Pharmaceuticals (NASDAQ:CNCE) Frequently Asked Questions
What is Concert Pharmaceuticals' stock symbol?
Concert Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNCE."
How were Concert Pharmaceuticals' earnings last quarter?
Concert Pharmaceuticals Inc (NASDAQ:CNCE) issued its quarterly earnings results on Thursday, May, 3rd. The biotechnology company reported ($0.19) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.58) by $0.39. The biotechnology company had revenue of $10.48 million for the quarter. Concert Pharmaceuticals had a negative return on equity of 23.57% and a net margin of 67.71%. View Concert Pharmaceuticals' Earnings History.
What price target have analysts set for CNCE?
4 brokers have issued 1-year target prices for Concert Pharmaceuticals' shares. Their forecasts range from $26.00 to $34.00. On average, they expect Concert Pharmaceuticals' stock price to reach $28.50 in the next year. View Analyst Ratings for Concert Pharmaceuticals.
What are Wall Street analysts saying about Concert Pharmaceuticals stock?
Here are some recent quotes from research analysts about Concert Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Concert Pharmaceuticals Inc. is a biopharmaceutical company. It is focused on applying its DCE Platform (R) to create novel small molecule drugs. The Company manufactures drugs in various therapeutic areas such as hot flashes, HIV, renal hepatic, neuropathic pain, MRSA infection, and schizophrenia, multiple tumors, and hyperparathyroidism. Concert Pharmaceuticals Inc. is based in United States. " (5/2/2018)
- 2. Mizuho analysts commented, "We don’t see a read-through from today’s news to the ultimate outcome of the IPR challenge. Based on how Concert has defended its patents historically and the impressive track record on IP protection front, we think it is likely they can win this challenge. PTAB Proceedings. In April 2017, Incyte filed an Inter Partes Review Petition (IPR) against Concert seeking to invalidate Concert’s U.S. Patent No. 9,249,149. Following this, in October 2017, the PTAB denied Incyte’s petition to institute the IPR. Today, the PTAB is granting Incyte’s motion for reconsideration. Oral arguments between the parties will be made in December followed by a PTAB decision, expected in April 2019. PLEASE REFER TO PAGE 3 OF THIS REPORT FOR IMPORTANT DISCLOSURE AND ANALYST CERTIFICATION INFORMATION. Mizuho Securities USA LLC does and seeks to do business with companies covered in its research reports." (4/10/2018)
Who are some of Concert Pharmaceuticals' key competitors?
Some companies that are related to Concert Pharmaceuticals include Myokardia (MYOK), Deciphera Pharmaceuticals (DCPH), PTC Therapeutics (PTCT), AnaptysBio (ANAB), Zogenix (ZGNX), Myovant Sciences (MYOV), G1 Therapeutics (GTHX), Mallinckrodt (MNK), Aimmune Therapeutics (AIMT), Biohaven Pharmaceutical (BHVN), Cambrex (CBM), ImmunoGen (IMGN), TherapeuticsMD (TXMD), Mirati Therapeutics (MRTX) and ARMO Biosciences (ARMO).
Who are Concert Pharmaceuticals' key executives?
Concert Pharmaceuticals' management team includes the folowing people:
- Mr. Richard H. Aldrich, Co-Founder & Chairman (Age 64)
- Dr. Roger D. Tung, Co-Founder, CEO, Pres & Director (Age 58)
- Ms. Nancy Stuart, Chief Operating Officer (Age 60)
- Dr. James V. Cassella, Chief Devel. Officer (Age 63)
- Mr. Marc A. Becker, Chief Financial Officer (Age 46)
Has Concert Pharmaceuticals been receiving favorable news coverage?
News coverage about CNCE stock has been trending somewhat positive on Saturday, according to Accern Sentiment. The research group identifies negative and positive press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Concert Pharmaceuticals earned a daily sentiment score of 0.18 on Accern's scale. They also gave news headlines about the biotechnology company an impact score of 46.81 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
Who are Concert Pharmaceuticals' major shareholders?
Concert Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BVF Inc. IL (8.32%), BlackRock Inc. (6.82%), Dimensional Fund Advisors LP (3.15%), Northern Trust Corp (2.72%), Franklin Resources Inc. (2.47%) and Millennium Management LLC (1.85%). Company insiders that own Concert Pharmaceuticals stock include James V Cassella, Richard Aldrich, Ronald W Barrett, Ryan Lynch and Value Fund L P Biotechnology. View Institutional Ownership Trends for Concert Pharmaceuticals.
Which major investors are selling Concert Pharmaceuticals stock?
CNCE stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Lyon Street Capital LLC, BlackRock Inc., UBS Group AG, Senzar Asset Management LLC, Wells Fargo & Company MN, BVF Inc. IL and Franklin Resources Inc.. Company insiders that have sold Concert Pharmaceuticals company stock in the last year include James V Cassella, Richard Aldrich, Ronald W Barrett, Ryan Lynch and Value Fund L P Biotechnology. View Insider Buying and Selling for Concert Pharmaceuticals.
Which major investors are buying Concert Pharmaceuticals stock?
CNCE stock was purchased by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Matarin Capital Management LLC, Northern Trust Corp, Spark Investment Management LLC, Russell Investments Group Ltd., Thrivent Financial for Lutherans, ClariVest Asset Management LLC and Citadel Advisors LLC. View Insider Buying and Selling for Concert Pharmaceuticals.
How do I buy shares of Concert Pharmaceuticals?
Shares of CNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Concert Pharmaceuticals' stock price today?
One share of CNCE stock can currently be purchased for approximately $19.37.
How big of a company is Concert Pharmaceuticals?
Concert Pharmaceuticals has a market capitalization of $459.49 million and generates $143.89 million in revenue each year. The biotechnology company earns $95.63 million in net income (profit) each year or $4.08 on an earnings per share basis. Concert Pharmaceuticals employs 64 workers across the globe.
How can I contact Concert Pharmaceuticals?
Concert Pharmaceuticals' mailing address is 99 HAYDEN AVENUE SUITE 500, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-860-0045 or via email at [email protected]
MarketBeat Community Rating for Concert Pharmaceuticals (CNCE)
MarketBeat's community ratings are surveys of what our community members think about Concert Pharmaceuticals and other stocks. Vote "Outperform" if you believe CNCE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CNCE will underperform the S&P 500 over the long term. You may vote once every thirty days.
